Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.
about
Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of lifePatient preferences in severe COPD and asthma: a comprehensive literature reviewComparing usability of NEXThaler(®) with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients.Concept review of dry powder inhalers: correct interpretation of published data.Recent advances in capsule-based dry powder inhaler technology.Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment.COPD: maximization of bronchodilation.Ease-of-use, preference, confidence, and satisfaction with Revolizer(®), a novel dry powder inhaler, in an Indian populationEase-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older.Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.Dry powder inhalers and the right things to remember: a concept review.A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study.Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMAAcceptability and preference of three inhalation devices assessed by the Handling Questionnaire in asthma and COPD patients.The economic impact of educational training assessed by the Handling Questionnaire with three inhalation devices in asthma and Chronic Obstructive Pulmonary Disease patients.Indacaterol: a comprehensive review.Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium.Role of once-daily glycopyrronium bromide (NVA237) in the management of COPDDry-powder inhalers in patients with persistent airflow limitation: usability and preference.A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trialOptimizing identification and management of COPD patients - reviewing the role of the community pharmacist.Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.Devices for dry powder drug delivery to the lung.Confidence in correct inhaler technique and its association with treatment adherence and health status among US patients with chronic obstructive pulmonary disease.The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients.Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD.Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
P2860
Q26801134-C498B6DF-D8E4-402A-9981-23C2F2FFFE12Q27004230-DD385E4E-E03E-4CFC-A9D2-AE369B0E93DCQ30429709-95D4538C-33ED-4371-8EEA-8424C9B64B8CQ31030099-E1E6F33C-7945-4443-A665-28C3528AEF6BQ33711473-9D1CB6D8-5874-4370-A380-095E53815D02Q33883565-EA6DDC9A-5989-4B04-B06F-F8463114F455Q34436393-34EFD910-DC25-4903-84B2-A191938E0825Q34453118-8AAD3A9F-0DD6-4613-BE38-E8D85AB04C77Q34710866-931A98F9-5719-472A-910D-30EA7AA96E8AQ35061912-9EFE1FA5-B464-4BC1-822B-C90CB2279F2DQ35426748-C7AD4707-422E-4790-9342-FFF549E635D8Q35816973-971CFFA4-CD11-4845-91FE-69FD58790C69Q35822146-C18A5F6E-88DE-469C-89DB-594813FEC22CQ36557694-8BD68AE4-98C0-4CDB-82FA-1819A2438EC3Q36566243-5EBE9E04-C768-45DB-94BB-98D6C32F6CF4Q36908050-9EB60831-E051-41BE-B713-8C43B3CB8708Q37057061-DACC198D-C1EF-49DC-A3CC-A00A18201E38Q37077219-A864A16E-DF25-4686-9C17-7292722F8D73Q37120706-3526B741-72A9-4F8C-A8F1-5A524E62C15EQ37232076-D9AD8A5B-262D-4BEC-936B-6C52BCA1E18FQ37437109-B448A461-4F3A-4355-A9F0-10C019EC5957Q37446886-04DEC3BF-FE54-497F-90C9-16A75847293EQ37579554-C9008358-3DE1-458D-A47C-AF3F3BD656D4Q38057220-D51362A7-FEE4-4D72-B654-6FD532A0BE71Q38474246-53E34537-C2E3-4456-8157-6E4294E37C7EQ41037310-2A9D5457-2015-4BD4-AC8C-D6E2F30DAC01Q41908094-99BE39D6-6B02-4DC2-A6CD-B5DCE68D0E06Q55120067-6D8E5F7D-8373-4B9A-85BB-124DED6D43BFQ55397939-8319CE48-77AA-4FC6-9726-87B0EA5554EE
P2860
Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Delivery characteristics and p ...... -powder inhalers used in COPD.
@ast
Delivery characteristics and p ...... -powder inhalers used in COPD.
@en
type
label
Delivery characteristics and p ...... -powder inhalers used in COPD.
@ast
Delivery characteristics and p ...... -powder inhalers used in COPD.
@en
prefLabel
Delivery characteristics and p ...... -powder inhalers used in COPD.
@ast
Delivery characteristics and p ...... -powder inhalers used in COPD.
@en
P2093
P2860
P356
P1476
Delivery characteristics and p ...... -powder inhalers used in COPD.
@en
P2093
Benjamin Kramer
Charles M Fogarty
Cheryl Lassen
Clare Peckitt
Dalal Jadayel
Juergen Dederichs
Mukul Dalvi
P2860
P304
P356
10.2147/COPD.S18529
P407
P577
2011-06-23T00:00:00Z